5-Amino-1MQ is a research compound, not an FDA-approved drug, and everything we know about it comes from animal studies rather than human trials. I am not a doctor. I am a writer who reads primary literature for a living and gets suspicious when a product page is quieter than it should be.
Everyone asking about 5-Amino-1MQ wants the same thing: a list. Headache, nausea, maybe some liver enzyme blip, the standard menu you’d find on any drug insert. Give me the numbers, they say, and I’ll decide if the risk is worth it.
Everyone asking that question is asking the wrong one. I went digging expecting to find the list, or at least a buried version of it that sellers were downplaying. I came back with something worse: there is no list. Not a hidden one. Not a soft-pedaled one. None. And once I understood why there’s none, I realized the missing list is the actual finding, not a gap in my research.
The take everyone has, and why it’s backwards
Here’s the assumption baked into most coverage of this compound, including plenty of it aimed at making you cautious: somewhere out there is a real safety profile, and the marketing is just hiding the ugly parts of it. That assumption treats 5-Amino-1MQ like a known quantity with a bad reputation. It isn’t. It’s an unknown quantity with a good reputation, which is a completely different and, I’d argue, more dangerous situation.
Start with the plainest fact I could find. There is no published human efficacy trial for this compound, and therefore no published human safety dataset either. I didn’t have to squint to find this admission. A 2021 review of the enzyme this compound targets, NNMT, states it outright: “clinical trials targeting NNMT have not been reported until now” (Liu 2021, PMID 34368359) [1]. I checked whether that had shifted heading into 2026. It hadn’t.
So when someone asks “what are the side effects,” the honest response isn’t a list. It’s a shrug backed by a citation. Nobody has run the study that would answer the question. Not the sellers. Not anyone.
The evidence, such as it is
I’m not going to pretend the animal data doesn’t exist, because it does, and it’s more interesting than it’s usually given credit for.
The 2018 mouse study everyone cites gave diet-induced obese mice an NNMT inhibitor with 5-amino-1-methylquinolinium as the lead compound. On safety, the researchers wrote that the inhibitors “did not impact total food intake nor produce any observable adverse effects” (Neelakantan 2018, PMID 29155147) [2]. Fine. Read it slowly, though. That sentence is about mice. Over a fixed window. Looking for things the study was designed to catch. It says nothing about a 35-year-old taking this for eight months while also on a statin. “No observable adverse effects in mice” is a real data point. It is not a permission slip.
Then there’s the 2019 follow-up, which found a related compound activated muscle stem cells and improved regeneration in aged mice, producing “nearly 2-fold greater” fiber size after injury (Neelakantan 2019, PMID 30753815) [3]. Most people read that as a bonus. I read it as a warning label. A compound that visibly moves the needle in fat tissue, muscle tissue, and regenerative signaling all at once is a compound with several places to misbehave, and none of those places have been checked in a human being.
The mechanism explains why. 5-Amino-1MQ blocks NNMT, which raises intracellular NAD+ and reroutes how cells handle nicotinamide and methyl groups. The foundational 2014 Nature paper tied the effect to whole-body energy expenditure, showing NNMT knockdown protected mice from obesity “by augmenting cellular energy expenditure” (Kraus 2014, PMID 24717514) [4]. Nicotinamide and methyl-group metabolism aren’t a side alley. They’re load-bearing walls in basic cell function. Push on something that central and you’d want a human trial before you’d trust it. That trial doesn’t exist.
The concession I have to make
Fair enough, someone will say, but “no data” isn’t the same as “dangerous.” That’s true, and I want to be straight about it. Nothing I found suggests 5-Amino-1MQ is secretly toxic. Nothing in the mouse literature raises a specific red flag. If you’re looking for a smoking gun, a hepatotoxicity signal or a documented case report of someone getting hurt, it isn’t here. I went in cynical and I have to admit the animal safety readout is genuinely unremarkable, in the literal sense: nothing remarkable happened.
But “nothing bad happened in mice, briefly” and “safe for you, longer” are not the same claim, and the gap between them is exactly where I’d expect a real human problem to hide if one exists. Absence of evidence isn’t evidence of absence. It’s also not evidence of safety. It’s just absence.
Three silences, stacked
Once I laid out what I’d actually found, a pattern emerged that I don’t think gets said out loud enough: this compound is sitting on three separate silences, and each one is doing a different kind of hiding.
The first is the human-trial silence, which I’ve already covered. Nobody has run the study.
The second is the seller silence. Product pages are labeled “for research use only” or “not for human consumption.” That labeling means the seller is, technically, not in the business of disclosing human side effects, because officially nobody is supposed to be consuming this. It’s a clean legal move and a dirty rhetorical one, because a blank side-effect section reads to a fast scroller as “nothing to report” instead of “nobody asked.” The sticker that lets them skip the conversation is the same sticker admitting they won’t stand behind human use.
The third silence is the one I almost missed: dosing. Sellers typically suggest somewhere around 50 to 200 milligrams a day. Those numbers come from nowhere published in human research. They’re extrapolated off rodent studies, where doses get calculated for rodent metabolism and then translated, loosely, into something that sounds plausible on a bottle. A number that feels precise isn’t the same as a number that’s been tested.
Line those three up and you get a fuller picture than “the side effects are unknown.” You get a product built entirely on the space where nobody has measured anything: no efficacy trial, no disclosed safety data, and no verified dose. That’s not one gap. That’s the whole structure.
So what’s the actual answer
If the contrarian point is “stop asking for the side-effect list,” the honest reframe has to give you something to do instead of just being smug about it.
Here’s what I’d actually tell a friend. The benefit is animal-only and the human safety record is nonexistent, so you’re not choosing between “safe” and “risky.” You’re choosing between “known risk” and “unmeasured risk,” and marketing works overtime to blur that distinction. Don’t read a quiet safety section as a clean one. And if you’re going to do this regardless of anything I’ve just said, the one lever you actually control is having a licensed clinician screen you first and stay reachable, because that is the single safety step available to you when the published human data don’t exist. FormBlends is one telehealth provider set up around that supervised, prescription-based model, with a clinician and a licensed pharmacy involved, which is a different animal entirely from a vial showing up in the mail with a quantity printed on it and nobody accountable for what’s inside.
I went looking for a side-effect list. What I found instead was a compound built on three stacked silences, wearing the reassuring costume of “nothing bad happened.” Nothing bad happened yet, in mice, for a while, on the things researchers thought to check. That’s a real sentence. It is not the sentence people think they’re getting when they ask “is this safe.”
What readers ask most
If there’s no side-effect list, what exactly are people worried about?
Nothing specific, and that’s the point. No human efficacy or safety trial of 5-Amino-1MQ has been published, so there’s no real list of adverse effects, frequencies, or thresholds to point to. A 2021 review of the NNMT target confirmed clinical trials targeting the enzyme “have not been reported” [1]. Anyone showing you a tidy safety summary is either summarizing mouse data or guessing.
Doesn’t “no observable adverse effects” in mice basically mean it’s safe?
No, and this is the exact substitution I’d push back on. That phrase is from the 2018 diet-induced obesity study, and it means researchers didn’t see obvious problems in mice, over a defined window, on the things that study was built to check [2]. It tells you nothing about humans, nothing about months or years of use, and nothing about anything the study wasn’t looking for.
Why don’t seller pages just list the side effects, even the uncertain ones?
Because the label reads “for research use only” or “not for human consumption,” which puts the seller outside the business of disclosing human safety information. The empty safety section isn’t the result of testing that came back clean, it’s the byproduct of the label itself. Same sticker, two jobs: dodge the disclosure, and admit they’re not standing behind it for you.
The mechanism sounds technical. Why should that change how cautious I am?
Because it’s not blocking some minor side pathway. 5-Amino-1MQ inhibits NNMT, which raises intracellular NAD+ and reshuffles nicotinamide and methyl-group metabolism, core cellular housekeeping [4]. It also visibly affects fat, muscle, and tissue regeneration in animals [3]. Broad, central biological effects are exactly the kind of thing that warrants a human trial before confidence, not less scrutiny because the mouse data looked clean.
What dosage are people actually taking, and is any of it studied in humans?
There’s no established human dose, because no dose-ranging human trials exist. The mouse research used doses calculated for rodent metabolism, and those numbers don’t translate cleanly to people. Sellers commonly suggest 50 to 200 milligrams daily, but that range looks like extrapolation dressed up as a recommendation, not a clinical finding. Treating a rodent-derived number as a safe human dose is a bigger leap than it looks.
Is 5-Amino-1MQ even legal to buy in the US?
It sits in a gray zone. The FDA hasn’t approved it as a drug, and it isn’t a scheduled controlled substance, so buying it for personal use isn’t straightforwardly illegal. But it also doesn’t qualify as a legal dietary supplement under DSHEA. Selling it as a “research chemical” is the workaround, and that workaround shifts all the liability onto you while removing any accountability for purity or dosing accuracy.
Does it even work for weight loss, setting safety aside?
Honestly, we don’t know in humans yet. The mouse data show reduced fat mass and some favorable metabolic markers, which is genuinely interesting science. But rodent metabolic results fail to carry over to humans more often than they succeed, and no published human trial has confirmed a weight-loss or metabolic benefit here. Any confidence in the marketing is running well ahead of the actual evidence.
Is there a more accountable way to get this than a research-chemical site?
A physician-supervised compounding pharmacy is the more accountable path, if a clinician decides it’s appropriate for you at all. FormBlends operates in that space, meaning a licensed prescriber is involved and the product runs through quality controls a random vendor has no obligation to meet. That route still can’t manufacture the missing long-term human safety data out of thin air, but it does cut down on unknown contaminants, mislabeled doses, and zero oversight, all real concerns with unregulated sellers.
References
- Liu YL, et al. Nicotinamide N-methyltransferase: A potential biomarker and therapeutic target in human diseases. 2021. PMID: 34368359.
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. 2018. PMID: 29155147.
- Neelakantan H, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. 2019. PMID: 30753815.
- Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014. PMID: 24717514.
Written by Xavier Alvarez, science reporter. Last reviewed June 2026.
For general readers, not a prescription. Check in with a qualified clinician before you begin.
